Skip to main content
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses

New Research In

Physical Sciences

Featured Portals

  • Physics
  • Chemistry
  • Sustainability Science

Articles by Topic

  • Applied Mathematics
  • Applied Physical Sciences
  • Astronomy
  • Computer Sciences
  • Earth, Atmospheric, and Planetary Sciences
  • Engineering
  • Environmental Sciences
  • Mathematics
  • Statistics

Social Sciences

Featured Portals

  • Anthropology
  • Sustainability Science

Articles by Topic

  • Economic Sciences
  • Environmental Sciences
  • Political Sciences
  • Psychological and Cognitive Sciences
  • Social Sciences

Biological Sciences

Featured Portals

  • Sustainability Science

Articles by Topic

  • Agricultural Sciences
  • Anthropology
  • Applied Biological Sciences
  • Biochemistry
  • Biophysics and Computational Biology
  • Cell Biology
  • Developmental Biology
  • Ecology
  • Environmental Sciences
  • Evolution
  • Genetics
  • Immunology and Inflammation
  • Medical Sciences
  • Microbiology
  • Neuroscience
  • Pharmacology
  • Physiology
  • Plant Biology
  • Population Biology
  • Psychological and Cognitive Sciences
  • Sustainability Science
  • Systems Biology
Research Article

Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors

View ORCID ProfileThomas C. T. Michaels, View ORCID ProfileAndela Šarić, View ORCID ProfileGeorg Meisl, View ORCID ProfileGabriella T. Heller, Samo Curk, Paolo Arosio, View ORCID ProfileSara Linse, Christopher M. Dobson, View ORCID ProfileMichele Vendruscolo, and Tuomas P. J. Knowles
PNAS September 29, 2020 117 (39) 24251-24257; first published September 14, 2020; https://doi.org/10.1073/pnas.2006684117
Thomas C. T. Michaels
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
bSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas C. T. Michaels
Andela Šarić
cDepartment of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London WC1E 6BT, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andela Šarić
Georg Meisl
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Georg Meisl
Gabriella T. Heller
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriella T. Heller
Samo Curk
cDepartment of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London WC1E 6BT, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Arosio
dDepartment of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zürich, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Linse
eDepartment of Chemistry, Division for Biochemistry and Structural Biology, Lund University, 221 00 Lund, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara Linse
Christopher M. Dobson
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Vendruscolo
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michele Vendruscolo
  • For correspondence: mv245@cam.ac.uk tpjk2@cam.ac.uk
Tuomas P. J. Knowles
aDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom;
fCavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, CB3 0HE, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mv245@cam.ac.uk tpjk2@cam.ac.uk
  1. Edited by Alexander M. Klibanov, Massachusetts Institute of Technology, Cambridge, MA, and approved August 17, 2020 (received for review April 8, 2020)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Significance

Developing effective strategies against human disorders linked with amyloid aggregation, including Alzheimer’s and Parkinson’s diseases, has proven to be difficult. A major reason is that traditional drug-discovery methods are poorly suited to deal with complex reaction networks such as those in involved in the aggregation process. It therefore remains challenging to identify suitable targets for drug development. To overcome this difficulty, we lay out here a general theory for inhibition of protein aggregation into amyloid fibrils, which uncovers quantitative thermodynamic and kinetic design principles to guide the rational search and optimization of effective inhibitors of fibril formation.

Abstract

Understanding the mechanism of action of compounds capable of inhibiting amyloid-fibril formation is critical to the development of potential therapeutics against protein-misfolding diseases. A fundamental challenge for progress is the range of possible target species and the disparate timescales involved, since the aggregating proteins are simultaneously the reactants, products, intermediates, and catalysts of the reaction. It is a complex problem, therefore, to choose the states of the aggregating proteins that should be bound by the compounds to achieve the most potent inhibition. We present here a comprehensive kinetic theory of amyloid-aggregation inhibition that reveals the fundamental thermodynamic and kinetic signatures characterizing effective inhibitors by identifying quantitative relationships between the aggregation and binding rate constants. These results provide general physical laws to guide the design and optimization of inhibitors of amyloid-fibril formation, revealing in particular the important role of on-rates in the binding of the inhibitors.

  • amyloid
  • inhibition
  • drug discovery
  • mathematical model
  • molecular mechanism

Footnotes

  • ↵1To whom correspondence may be addressed. Email: mv245{at}cam.ac.uk or tpjk2{at}cam.ac.uk.
  • Author contributions: T.C.T.M., S.L., C.M.D., M.V., and T.P.J.K. designed research; T.C.T.M. performed research; G.T.H. contributed new reagents/analytic tools; T.C.T.M. analyzed data; and T.C.T.M., A.S., G.M., G.T.H., S.C., P.A., S.L., C.M.D., M.V., and T.P.J.K. wrote the paper.

  • The authors declare no competing interest.

  • This article is a PNAS Direct Submission.

  • This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2006684117/-/DCSupplemental.

Data Availability.

All study data are included in the article and SI Appendix.

Published under the PNAS license.

View Full Text

References

  1. ↵
    1. C. M. Dobson
    , Protein folding and misfolding. Nature 426, 884–890 (2003).
    OpenUrlCrossRefPubMed
  2. ↵
    1. D. Eisenberg,
    2. M. Jucker
    , The amyloid state of proteins in human diseases. Cell 148, 1188–1203 (2012).
    OpenUrlCrossRefPubMed
  3. ↵
    1. T. P. J. Knowles,
    2. M. Vendruscolo,
    3. C. M. Dobson
    , The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384–396 (2014).
    OpenUrlCrossRefPubMed
  4. ↵
    1. D. J. Selkoe,
    2. J. Hardy
    , The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. F. Chiti,
    2. C. M. Dobson
    , Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu. Rev. Biochem. 86, 27–68 (2017).
    OpenUrlCrossRefPubMed
  6. ↵
    1. C. M. Dobson
    , The amyloid phenomenon and its links with human disease. Cold Spring Harb. Perspect. Biol. 9, a023648 (2017).
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. A. Aguzzi,
    2. T. O’Connor
    , Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 9, 237–248 (2010).
    OpenUrlCrossRefPubMed
  8. ↵
    1. P. Arosio,
    2. M. Vendruscolo,
    3. C. M. Dobson,
    4. T. P. J. Knowles
    , Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127–135 (2014).
    OpenUrlCrossRefPubMed
  9. ↵
    1. S. Linse
    , Mechanism of amyloid protein aggregation and the role of inhibitors. Pure Appl. Chem. 91, 211–229 (2019).
    OpenUrl
  10. ↵
    1. S. Giorgetti,
    2. C. Greco,
    3. P. Tortora,
    4. F. A. Aprile
    , Targeting amyloid aggregation: An overview of strategies and mechanisms. Int. J. Mol. Sci. 19, 2677 (2018).
    OpenUrlCrossRefPubMed
  11. ↵
    1. M. Necula,
    2. R. Kayed,
    3. S. Milton,
    4. C. G. Glabe
    , Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311–10324 (2007).
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. J. Cummings,
    2. J. K. Zhong,
    3. C. Bernick
    , The Cleveland Clinic Lou Ruvo Center for Brain Health: Keeping memory alive. J. Alzheimers Dis. 38, 103–109 (2014).
    OpenUrl
  13. ↵
    1. Y. Huang,
    2. L. Mucke
    , Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–1222 (2012).
    OpenUrlCrossRefPubMed
  14. ↵
    1. R. E. Becker,
    2. N. H. Greig,
    3. E. Giacobini,
    4. L. S. Schneider,
    5. L. Ferrucci
    , A new roadmap for drug development for Alzheimer’s disease. Nat. Rev. Drug Discov. 13, 156 (2014).
    OpenUrl
  15. ↵
    1. T. Härd,
    2. C. Lendel
    , Inhibition of amyloid formation. J. Mol. Biol. 421, 441–465 (2012).
    OpenUrlCrossRefPubMed
  16. ↵
    1. H. Amijee,
    2. D. I. Scopes
    , The quest for small molecules as amyloid inhibiting therapies for Alzheimer’s disease. J. Alzheimers Dis. 17, 33–47 (2009).
    OpenUrlPubMed
  17. ↵
    1. F. Mangialasche,
    2. A. Solomon,
    3. B. Winblad,
    4. P. Mecocci,
    5. M. Kivipelto
    , Alzheimer’s disease: Clinical trials and drug development. Lancet Neurol. 9, 702–716 (2010).
    OpenUrlCrossRefPubMed
  18. ↵
    1. B. Bulic et al.
    , Development of tau aggregation inhibitors for Alzheimer’s disease. Angew. Chem. Int. Ed. 48, 1740–1752 (2009).
    OpenUrlCrossRefPubMed
  19. ↵
    1. H. A. Lashuel,
    2. C. R. Overk,
    3. A. Oueslati,
    4. E. Masliah
    , The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48 (2013).
    OpenUrlCrossRefPubMed
  20. ↵
    1. Q. Nie,
    2. X. G. Du,
    3. M. Y. Geng
    , Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer’s disease. Acta Pharmacol. Sin. 32, 545–551 (2011).
    OpenUrlCrossRefPubMed
  21. ↵
    1. E. Karran,
    2. J. Hardy
    , A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76, 185–205 (2014).
    OpenUrlCrossRefPubMed
  22. ↵
    1. F. Panza,
    2. M. Lozupone,
    3. G. Loogroscino,
    4. B. P. Imbimbo
    , A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73–88 (2019).
    OpenUrlCrossRefPubMed
  23. ↵
    1. L. S. Honig et al.
    , Trial of solanezumab for mild dementia due to Alzheimer’s disease. New. Eng. Med. 378, 321–330 (2018).
    OpenUrl
  24. ↵
    1. S. Linse et al.
    , Kinetic fingerprint of antibody therapies predicts outcomes of Alzheimer clinical trials. bioRxiv. https://doi.org/10.1101/815308 (22 Oct 2019).
  25. ↵
    1. J. Habchi et al.
    , Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 114, E200–E208 (2016).
    OpenUrl
  26. ↵
    1. M. Perni et al.
    , A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc. Natl. Acad. Sci. U.S.A. 114, E1009–E1017 (2017).
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. J. Habchi et al.
    , An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s disease. Sci. Adv. 2, e1501244 (2016).
    OpenUrlFREE Full Text
  28. ↵
    1. S. Chia et al.
    , SAR by kinetics for drug discovery in protein misfolding diseases. Proc. Natl. Acad. Sci. U.S.A. 115, 10245–10250 (2018).
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. P. Arosio et al.
    , Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016).
    OpenUrlCrossRefPubMed
  30. ↵
    1. S. I. A. Cohen et al.
    , A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat. Struct. Mol. Biol. 22, 207–213 (2015).
    OpenUrlCrossRefPubMed
  31. ↵
    1. F. A. Aprile et al.
    , Inhibition of α-synuclein fibril elongation by Hsp70 is governed by a kinetic binding competition between α-synuclein species. Biochemistry 56, 1177–1180 (2017).
    OpenUrlCrossRefPubMed
  32. ↵
    1. P. Sormanni,
    2. F. A. Aprile,
    3. M. Vendruscolo
    , Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc. Natl. Acad. Sci. U.S.A. 112, 9902–9907 (2015).
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. F. A. Aprile et al.
    , Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method. Sci. Adv. 3, e1700488 (2017).
    OpenUrlFREE Full Text
  34. ↵
    1. T. John et al.
    , Impact of nanoparticles on amyloid peptide and protein aggregation: A review with a focus on gold nanoparticles. Nanoscale 10, 20894–20913 (2018).
    OpenUrl
  35. ↵
    1. D. M. Walsh et al.
    , Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
    OpenUrlCrossRefPubMed
  36. ↵
    1. I. Benilova,
    2. E. Karran,
    3. B. De strooper
    , The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 15, 349–357 (2012).
    OpenUrlCrossRefPubMed
  37. ↵
    1. S. Campioni et al.
    , A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 6, 140–147 (2010).
    OpenUrlCrossRefPubMed
  38. ↵
    1. G. Fusco et al.
    , Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science 358, 1440–1443 (2017).
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. T. C. T. Michaels et al.
    , Chemical kinetics for bridging molecular mechanisms and macroscopic measurements of amyloid fibril formation. Annu. Rev. Phys. Chem. 69, 273–298 (2018).
    OpenUrlCrossRefPubMed
  40. ↵
    1. F. Oosawa,
    2. S. Asakura
    , Thermodynamics of the Polymerization of Protein (Academic Press, New York, NY, 1975).
  41. ↵
    1. T. P. J. Knowles et al.
    , An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533–1537 (2009).
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. S. I. A. Cohen et al.
    , Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J. Chem. Phys. 135, 065105 (2011).
    OpenUrlCrossRefPubMed
  43. ↵
    1. S. I. A. Cohen et al.
    , Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 110, 9758–9763 (2013).
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. F. A. Ferrone,
    2. J. Hofrichter,
    3. W. A. Eaton
    , Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. J. Mol. Biol. 183, 611–631 (1985).
    OpenUrlCrossRefPubMed
  45. ↵
    1. A. M. Ruschak,
    2. A. D. Miranker
    , Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. Proc. Natl. Acad. Sci. U.S.A. 104, 12341–12346 (2007).
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. M. Törnquist et al.
    , Secondary nucleation in amyloid formation. Chem. Comm. 54, 8667–8684 (2018).
    OpenUrl
  47. ↵
    1. A. Cacciuto,
    2. S. Auer,
    3. D. Frenkel
    , Onset of heterogeneous crystal nucleation in colloidal suspensions. Nature 428, 404–406 (2004).
    OpenUrlCrossRefPubMed
  48. ↵
    1. A. Sarić et al.
    , Physical determinants of the self-replication of protein fibrils. Nat. Phys. 12, 874–880 (2016).
    OpenUrl
  49. ↵
    1. A. Saric,
    2. Y. C. Chebaro,
    3. T. P. J. Knowles,
    4. D. Frenkel
    , Crucial role of nonspecific interactions in amyloid nucleation. Proc. Natl. Acad. Sci. U.S.A. 111, 17869–17874 (2014).
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. A. Saric,
    2. T. C. T. Michaels,
    3. A. Zaccone,
    4. T. P. J. Knowles,
    5. D. Frenkel
    , Kinetics of spontaneous filament nucleation via oligomers: Insights from theory and simulation. J. Chem. Phys. 145, 211926 (2016).
    OpenUrl
  51. ↵
    1. A. Lomakin,
    2. D. B. Teplow,
    3. D. A. Kirschner,
    4. G. B. Benedek
    , Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc. Natl. Acad. Sci. U.S.A. 94, 7942–7947 (1997).
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. T. C. T. Michaels et al.
    , Reaction rate theory for supramolecular kinetics: Application to protein aggregation. Mol. Phys. 116, 3055–3065 (2018).
    OpenUrl
  53. ↵
    1. T. C. T. Michaels,
    2. T. P. J. Knowles
    , Kinetic theory of protein filament growth: Self-consistent methods and perturbative techniques. Int. J. Mod. Phys. B 29, 1530002 (2015).
    OpenUrl
  54. ↵
    1. G. Meisl et al.
    , Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252–272 (2016).
    OpenUrlCrossRefPubMed
  55. ↵
    1. T. C. T. Michaels et al.
    , Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 peptide. Nat. Chem. 12, 445–451 (2020).
    OpenUrlCrossRefPubMed
  56. ↵
    1. G. T. Heller et al.
    , Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease. bioRxiv. https://www.biorxiv.org/content/10.1101/729392v3 (20 May 2020).
  57. ↵
    1. C. Galvagnion et al.
    , Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229–234 (2015).
    OpenUrlCrossRefPubMed
  58. ↵
    1. F. Grigolato,
    2. C. Colombo,
    3. R. Ferrari,
    4. L. Rezabkova,
    5. P. Arosio
    , Mechanistic origin of the combined effect of surfaces and mechanical agitation on amyloid formation. ACS Nano 11, 11358–11367 (2017).
    OpenUrlCrossRefPubMed
  59. ↵
    1. C. J. Roberts
    , Kinetics of irreversible protein aggregation: Analysis of extended Lumry-Eyring models and implications for predicting protein shelf life. J. Phys. Chem. B 107, 1194–1207 (2003).
    OpenUrl
  60. ↵
    1. J. M. Andrews,
    2. C. J. Roberts
    , A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J. Phys. Chem. B 111, 7897–7913 (2007).
    OpenUrlCrossRefPubMed
  61. ↵
    1. L. Nicoud et al.
    , Role of cosolutes in the aggregation kinetics of monoclonal antibodies. J. Phys. Chem. B 118, 11921–11930 (2014).
    OpenUrl

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Subscribers, for more details, please visit our Subscriptions FAQ.

Please click here to log into the PNAS submission website.

PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors
Thomas C. T. Michaels, Andela Šarić, Georg Meisl, Gabriella T. Heller, Samo Curk, Paolo Arosio, Sara Linse, Christopher M. Dobson, Michele Vendruscolo, Tuomas P. J. Knowles
Proceedings of the National Academy of Sciences Sep 2020, 117 (39) 24251-24257; DOI: 10.1073/pnas.2006684117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors
Thomas C. T. Michaels, Andela Šarić, Georg Meisl, Gabriella T. Heller, Samo Curk, Paolo Arosio, Sara Linse, Christopher M. Dobson, Michele Vendruscolo, Tuomas P. J. Knowles
Proceedings of the National Academy of Sciences Sep 2020, 117 (39) 24251-24257; DOI: 10.1073/pnas.2006684117
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences: 117 (39)
Table of Contents

Submit

Sign up for Article Alerts

Article Classifications

  • Biological Sciences
  • Biophysics and Computational Biology
  • Physical Sciences
  • Chemistry

Jump to section

  • Article
    • Abstract
    • Aggregation Kinetics in the Presence of an Inhibitor
    • Integrated Rate Laws for Inhibited-Aggregation Kinetics
    • The Interplay between Kinetics and Thermodynamics Generates a Rich Inhibition-Phase Behavior
    • Physical Design Principles for Effective Inhibitors and Illustrative Examples on Experimental Data
    • Summary and Outlook
    • Data Availability.
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Abstract depiction of a guitar and musical note
Science & Culture: At the nexus of music and medicine, some see disease treatments
Although the evidence is still limited, a growing body of research suggests music may have beneficial effects for diseases such as Parkinson’s.
Image credit: Shutterstock/agsandrew.
Scientist looking at an electronic tablet
Opinion: Standardizing gene product nomenclature—a call to action
Biomedical communities and journals need to standardize nomenclature of gene products to enhance accuracy in scientific and public communication.
Image credit: Shutterstock/greenbutterfly.
One red and one yellow modeled protein structures
Journal Club: Study reveals evolutionary origins of fold-switching protein
Shapeshifting designs could have wide-ranging pharmaceutical and biomedical applications in coming years.
Image credit: Acacia Dishman/Medical College of Wisconsin.
White and blue bird
Hazards of ozone pollution to birds
Amanda Rodewald, Ivan Rudik, and Catherine Kling talk about the hazards of ozone pollution to birds.
Listen
Past PodcastsSubscribe
Goats standing in a pin
Transplantation of sperm-producing stem cells
CRISPR-Cas9 gene editing can improve the effectiveness of spermatogonial stem cell transplantation in mice and livestock, a study finds.
Image credit: Jon M. Oatley.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Latest Articles
  • Archive

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490